Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 9/20 | 0.55 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.55 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.55 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.50 |
| ▸ | GNPAT | O15228 | 1/20 | 0.47 |
| ▸ | GGH | Q92820 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9696078 | 1.00 | FOLH1 (0.55) | FOLH1NAALAD2RIMKLANOD1GNPAT | |
| SCHEMBL9697168 | 1.00 | FOLH1 (0.55) | FOLH1NAALAD2RIMKLANOD1GNPAT | |
| SCHEMBL22315438 | 0.92 | FOLH1 (0.50) | FOLH1NAALAD2RIMKLANOD1GNPAT | |
| SCHEMBL5575587 | 0.89 | FOLH1 (0.55) | FOLH1NAALAD2RIMKLAGGH | |
| SCHEMBL1248320 | 0.89 | FOLH1 (0.55) | FOLH1NAALAD2RIMKLAGGH | |
| SCHEMBL9696087 | 0.89 | FOLH1 (0.55) | FOLH1NAALAD2RIMKLAGGH | |
| SCHEMBL24918919 | 0.88 | FOLH1 (0.43) | FOLH1NAALAD2RIMKLANOD1GNPAT | |
| Hydrochloric Acid SCHEMBL5575609 | 0.88 | FOLH1 (0.53) | FOLH1NAALAD2RIMKLAGGH | |
| Hydrochloric Acid SCHEMBL5575602 | 0.88 | FOLH1 (0.53) | FOLH1NAALAD2RIMKLAGGH | |
| SCHEMBL22308518 | 0.87 | NOD1 (0.48) | FOLH1NAALAD2RIMKLANOD1GNPAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239863-A1 | GIP RECEPTOR AGONIST AND USE THEREOF | HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO., LTD. (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20240239863-A1 | GIP RECEPTOR AGONIST AND USE THEREOF | HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO., LTD. (CN) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239863-A1 | GIP RECEPTOR AGONIST AND USE THEREOF | GIPR, GLP1R, GPR119 | FOLH1 956/4885NAALAD2 871/4885RIMKLA 2912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.